Emeis Stock Rises 2.7% to €14.81 Ahead of Q1 2026 Revenue Announcement
Emeis stock advanced 2.7% to €14.81 in mid-session trading on Tuesday, amidst a 0.62% rise in the CAC 40. The stock is nearing its resistance level of €15.06, just 24 hours before the Q1 2026 revenue release. Over the past year, the stock has gained 20.94%.
Stock Nears Resistance Ahead of Quarterly Earnings Release
The EMEIS stock is trading near the upper boundary of its Bollinger Bands, approximately 1% below the upper limit set at €14.93. The price has surpassed its 50-day moving average (€13.96) and its 200-day moving average (€13.61), indicating a bullish alignment that has supported the stock's rise since the end of April. The RSI at 57 remains neutral, showing no signs of exhaustion at this stage. The resistance threshold of €15.06 is within immediate reach, with the potential breach depending on the details of the upcoming announcement on Wednesday, May 6, when the group will disclose its Q1 2026 revenue.
Recovery Trajectory Confirmed by 2025 Financial Statements
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock's rebound follows the annual earnings release. In the 2025 financial statements, the group, which specializes in retirement homes and clinics, reported a 19.2% increase in EBITDAR on a like-for-like basis and a two-point increase in occupancy rates, despite a net loss of €298 million. For 2026, the company expects EBITDAR growth to exceed 10%. Governance is also evolving. Jean-Marc Boursier will assume the role of Deputy CEO on July 1, while Olivier Dussopt has been proposed at the general meeting to succeed Guillaume Pepy as chairman of the board. The stock had also consolidated at the end of April following a TP Icap Midcap recommendation targeting €17. The next key event: the Q1 revenue, to be published on May 6.
SectorSanté · Etablissements de santé / EHPAD›Etablissements de santé
Context
Period
Period: 9M 2025
Guidance from the release
Croissance organique soutenue (+6,4% à fin septembre 2025, +7,0% au T3), amélioration notable des taux d'occupation, objectifs de cessions dépassés (2,1 Md€) et confirmation des perspectives 2025 et de la trajectoire 2024-2028.
Risks mentioned
Risques et incertitudes liés aux conditions de marché futures pouvant affecter les résultats prévisionnels
Risque de non-réalisation ou de délai des cessions actuellement sécurisées ou en négociation
Impact transitoire des ouvertures récentes sur les taux d'occupation dans certaines zones
Opportunities identified
Croissance démographique des plus de 75 ans (+30% d'ici 10 ans) créant une demande structurelle accrue
Déficit structurel d'offre (déficit attendu de lits sur principaux marchés) offrant une forte visibilité commerciale
Possibilités de capture d'effets prix favorables et d'amélioration de marges opérationnelles
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
